Drug intelligence / Profile preview

Qilinghuaxian Formula

Development stage: Unknown
Lead developer: Ningbo No. 2 Hospital
Administration: Oral

Overview

Qilinghuaxian Formula is a Traditional Chinese Medicine (TCM) herbal composition developed by Ningbo No. 2 Hospital for the treatment of liver cirrhosis and fibrosis associated with chronic hepatitis B virus (HBV) infection. The formula is designed to exert anti-fibrotic effects by inhibiting the activation of hepatic stellate cells and reducing the accumulation of extracellular matrix in the liver. It is typically administered orally as a decoction or granule. Clinical research, including trial ChiCTR2200067068, investigates its potential to improve liver function and reverse histological damage in patients already receiving standard nucleos(t)ide analogue antiviral therapy.

Other names: Qiling Huaxian Formula麒苓化纤方

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on Qilinghuaxian Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qilinghuaxian Formula.

Explore the full profile